Business Context and Reporting Period
This Form 8-K, dated February 8, 2021, is filed by Anchiano Therapeutics Ltd. (the "Company") to announce a Special Meeting of Shareholders scheduled for March 15, 2021. The primary purpose of the meeting is to approve a merger with Chemomab Ltd. ("Chemomab") and related corporate actions. Upon completion, the Company intends to change its name to Chemomab Therapeutics Ltd.
Key Financial Metrics
The filing does not provide specific historical financial metrics such as revenue, profit, cash flow, margins, or debt levels for the reporting period. However, it outlines a proposed private placement financing to be approved at the Special Meeting, targeting aggregate gross proceeds of at least $30.0 million and up to $50.0 million.
Material Changes and Proposed Transactions
- Merger Approval: Shareholders will vote to approve the merger of CMB Acquisition Ltd. (a wholly-owned subsidiary of Anchiano) into Chemomab Ltd.
- Capital Raise: Approval is sought for the issuance of ordinary shares in a private placement to raise between $30.0 million and $50.0 million.
- Corporate Restructuring: The Company proposes to amend its articles of association to:
- Increase registered share capital from 500,000,000 to 650,000,000 ordinary shares.
- Effect a reverse stock split of ordinary shares at a ratio between 1-for-2 and 1-for-4.
- Adopt a classified board format for director elections.
- Change the corporate name to "Chemomab Therapeutics Ltd."
- Compensation and Governance: Proposals include amendments to the Compensation Policy to remove limits on directors and officers insurance premiums and to adjust compensation terms for directors.
Outlook, Risks, and Management Commentary
Management highlights that the transaction is subject to various risks and uncertainties. Key risks include the failure to obtain shareholder approval, the inability to satisfy closing conditions for the merger or financing, and the potential for unexpected costs. The Company notes that the combined entity will require additional capital to advance its product candidates, specifically CM-101 and RAS, with no assurance that such capital will be available on favorable terms. The filing contains forward-looking statements regarding the structure and timing of the merger, which are subject to change.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and the specific exchange ratio for Chemomab shareholders.
- Confirm the definitive proxy statement/prospectus for details on the private placement financing terms and the exact reverse split ratio.
- Review the "Risk Factors" section in the Company's recent 10-K and 10-Q filings for a comprehensive list of operational and financial risks.
- Monitor the outcome of the Special Meeting of Shareholders scheduled for March 15, 2021, to confirm transaction approval.
- Assess the combined company's cash runway and capital requirements for the development of CM-101 and RAS post-merger.